These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
4428 related items for PubMed ID: 15758010
21. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F. Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791 [Abstract] [Full Text] [Related]
22. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. Brawanski KR, Sprung S, Freyschlag CF, Hoeftberger R, Ströbel T, Haybaeck J, Thomé C, Manzl C, Birkl-Toeglhofer AM. Int J Mol Sci; 2023 Mar 24; 24(7):. PubMed ID: 37047153 [Abstract] [Full Text] [Related]
24. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. McAleenan A, Kelly C, Spiga F, Kernohan A, Cheng HY, Dawson S, Schmidt L, Robinson T, Brandner S, Faulkner CL, Wragg C, Jefferies S, Howell A, Vale L, Higgins JPT, Kurian KM. Cochrane Database Syst Rev; 2021 Mar 12; 3(3):CD013316. PubMed ID: 33710615 [Abstract] [Full Text] [Related]
25. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO. Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):661-7. PubMed ID: 22414280 [Abstract] [Full Text] [Related]
31. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. Zhao H, Wang S, Song C, Zha Y, Li L. World J Surg Oncol; 2016 Oct 12; 14(1):261. PubMed ID: 27733166 [Abstract] [Full Text] [Related]
34. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Fukushima T, Takeshima H, Kataoka H. Anticancer Res; 2009 Nov 12; 29(11):4845-54. PubMed ID: 20032445 [Abstract] [Full Text] [Related]
37. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Lancet Oncol; 2012 Jul 12; 13(7):707-15. PubMed ID: 22578793 [Abstract] [Full Text] [Related]
38. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. Adachi J, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T, Matsutani M, Sasaki A, Nishikawa R. J Neurooncol; 2012 Mar 12; 107(1):147-53. PubMed ID: 21968944 [Abstract] [Full Text] [Related]